Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
75 hedge funds and large institutions have $55.5M invested in Eagle Pharmaceuticals, Inc. in 2024 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 41 reducing their positions, and 30 closing their positions.
1% more capital invested
Capital invested by funds: $54.8M → $55.5M (+$737K)
18% less funds holding
Funds holding: 91 → 75 (-16)
53% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 30
73% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$4.35M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.06M |
| 3 |
PA
Perceptive Advisors
New York
|
+$755K |
| 4 |
RC
RBF Capital
San Francisco,
California
|
+$558K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.37M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$897K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$794K |
| 4 |
State Street
Boston,
Massachusetts
|
-$775K |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$645K |
EGRX Hedge Fund Activity: Q2 2024 in Review
75 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q2 2024, worth a combined $55.5M — up 1.3% from $54.8M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of EGRX and 14 opened new positions — a net loss of 16 holders — while 41 trimmed existing stakes and 11 added.
The largest buyer was Citigroup, adding an estimated $4.35M. The largest seller was BlackRock, cutting an estimated $2.37M.
- 75 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q2 2024, down from 91 in Q1 2024.
- Funds reported $55.5M of Eagle Pharmaceuticals, Inc. stock for Q2 2024, up 1.3% quarter-over-quarter.
- 14 funds opened new Eagle Pharmaceuticals, Inc. positions in Q2 2024 and 30 closed out, a net change of -16 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q2 2024 was Citigroup, an estimated $4.35M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q2 2024 was BlackRock, an estimated $2.37M sold.
Based on aggregated 13F filings for Q2 2024.